Year: 2025

Largest real-world analysis of AI-driven breast cancer screening in U.S. history1 demonstrates increased cancer detection rate with consistent benefits across patient populations LOS ANGELES and SOMERVILLE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), the nation’s largest provider of outpatient diagnostic imaging services, and its wholly owned subsidiary, DeepHealth, a global leader in AI-powered health informatics, today announced results from the largest real-world analysis of AI-driven breast cancer screening ever conducted in the United States.1 Published in Nature Health, the findings support the clinical effectiveness and benefit of DeepHealth’s AI technology to deliver equitable results across several racial, ethnic and breast density patient groups. The AI-Supported Safeguard Review Evaluation...

NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced it will host a virtual Research and Development (R&D) Event from 11:00 am – 1:45 pm ET on Friday, December 5, 2025. Candel’s R&D Day will include presentations and panel discussions from its executive leadership, clinical investigators, scientific advisors, and key collaborators. The event will provide an extensive overview of the Company’s viral immunotherapy approach and oncology-focused pipeline. Click here to register for the event. The R&D Day will include the following presentations: Introduction to Candel Therapeutics: Paul Peter Tak, MD, PhD, FMedSci,...

MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), advanced breast cancer (“ABC”). The NDA was submitted under the FDA’s Real-Time Oncology Review (“RTOR”) program, which is intended to facilitate shorter regulatory review periods. Gedatolisib previously received both Breakthrough Therapy and Fast Track designations based on promising preliminary clinical data. The submission is based on clinical data from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical...

CLEARWATER Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) — Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Lucid Capital Markets is acting as the sole book-running manager for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-268532) filed with the Securities and Exchange Commission (“SEC”) on November 22, 2022, and declared effective...

A high-quality portfolio consisting of North American Financial Services Companies TORONTO, Nov. 17, 2025 (GLOBE NEWSWIRE) — Financial 15 Split Corp. (the “Company”) is pleased to announce it will undertake an offering of Preferred Shares (TSX: FTN.PR.A) of the Company. The offering will be led by National Bank Financial Inc. The sales period of this overnight offering will end at 9:00 a.m. EST on November 18, 2025. The offering is expected to close on or about November 25, 2025 and is subject to certain closing conditions including approval by the TSX. The Preferred Shares will be offered at a price of $10.60 per Preferred Share. The closing price on the TSX of the Preferred Shares on November 14, 2025 was $10.72. Since the inception of the Company, 263 consecutive dividends have been declared for the Preferred Shares. The aggregate...

DAVENPORT, Iowa, Nov. 17, 2025 (GLOBE NEWSWIRE) — Lee Enterprises, Incorporated (NASDAQ: LEE), a major subscription and advertising platform and a leading provider of high quality, trusted, local news and information in 72 markets, has scheduled an audio webcast and conference call for Wednesday, November 26, 2025, at 9 a.m. Central Time. Lee plans to issue a news release before the market opens that day with preliminary results for its quarter ended September 28, 2025. A live webcast of the conference call may be accessed via the Investor Relations portion of Lee’s website or here. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. The live webcast will be accessible at lee.net and will be available for...

Company to deliver spider silk yarns for elite-tier athletic application ANN ARBOR, Mich., Nov. 17, 2025 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that it is fulfilling an order for spider silk from a globally recognized performance sports apparel brand as part of a confidential pilot development program. This project will incorporate the Company’s next-generation recombinant spider silk into a cutting-edge application targeted at the highest tier of performance apparel. While specific project details remain protected, Kraig Labs can confirm that the program is designed for one of the most demanding and innovation-focused segments of the athletic market. This customer’s market leadership,...

Partnership enables non-custodial staking of TON tokens through BitGo integration, advancing AlphaTON’s yield generation strategy New York, NY, Nov. 17, 2025 (GLOBE NEWSWIRE) — AlphaTON Capital (Nasdaq: ATON), a specialized digital asset treasury company accelerating the growth of The Open Network (TON) Telegram ecosystem, today announced the selection of P2P.org as an institutional staking partner to support the Company’s TON treasury yield generation operations.The partnership represents a significant milestone in AlphaTON Capital’s three-pillar treasury strategy, enabling the Company to generate sustainable yields on its TON holdings through P2P.org’s enterprise-grade validator infrastructure. The initial deployment of 4 million locked TON tokens will be facilitated through BitGo’s institutional...